This notice serves as a reminder of key requirements and features of the Arizona Controlled Substances Prescription Monitoring Program (CSPMP).

Mandatory Use:

• As a prescriber, you are required

The FDA has issued a letter to the Federation of State Medical Boards regarding compounded drug products containing retatrutide, which are being promoted for the treatment of chronic weight management

The Board utilizes Outside Medical Consultants for review of complaints before the Board. Please review the full brochure here. The Board is always seeking Outside Medical Consultants from all